María del Pilar
Herrera Puente
Profesor/a Asociado/a en CC. de la Salud
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital General Universitario Gregorio Marañón (17)
2024
-
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Cancer, Vol. 130, Núm. 20, pp. 3436-3451
-
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
Haematologica, Vol. 109, Núm. 2, pp. 543-552
-
Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia
Frontiers in Oncology, Vol. 14
2022
-
Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups
Cancers, Vol. 14, Núm. 22
-
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience
Cancers, Vol. 14, Núm. 11
-
Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC
Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10
2021
-
Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers
Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8
-
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study
Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928
-
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938
-
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Leukemia, Vol. 35, Núm. 6, pp. 1571-1585
-
Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 10, pp. e801-e809
-
Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant
Frontiers in Immunology, Vol. 12
2019
-
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Leukemia Research, Vol. 76, pp. 1-10
2017
-
Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML
Bone Marrow Transplantation, Vol. 52, Núm. 8, pp. 1138-1143
2016
-
Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience
Bone Marrow Transplantation, Vol. 51, Núm. 10, pp. 1307-1312
2014
-
Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: A bridge to individualized medicine
Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, Núm. 4, pp. 305-318